Relapsed/refractory multiple myeloma (RRMM) doesn’t have a cure. But many treatments can ease symptoms and slow the cancer’s growth. If the medicines you’re taking stop working, you and your doctor ...
Key opinion leaders dive into the use of bispecific treatment options for RRMM. Jeffrey Matous, MD: Let’s switch gears here and move on from CAR [chimeric antigen receptor] T cells to what I call the ...
Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management. Jonathan L. Kaufman, MD: At our institution, the way we use ...
If you have relapsed/refractory multiple myeloma (RRMM), you may be wondering how to balance treatment with your daily life. Here are some tips on what you can expect. When recommending a new ...
Panelists discuss how quality of life priorities shift in late-line multiple myeloma treatment, with patients emphasizing the importance of maintaining independence in daily activities, preserving ...
Panelists discuss how ciltacabtagene autoleucel (cilta-cel) demonstrates superior outcomes compared to real-world physician’s choice of therapy in patients with late-line relapsed/refractory multiple ...
For patients with relapsed or refractory multiple myeloma, treatment with teclistamab plus daratumumab is associated with a significant PFS benefit.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: BMY) today announced that the Phase 3 EXCALIBER-RRMM study evaluating iberdomide, an investigational cereblon E3 ligase modulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback